In Brief: Orphan Drug Tax Credit

Executive Summary

Orphan Drug Tax Credit: A bill establishing a permanent tax credit for orphan drug development is to be considered by Ways & Means Oversight Subcommittee at a May 9 hearing. The measure, HR 1566, was introduced May 3 by Oversight Chair Johnson (R-Conn.) and co-sponsored by subcommittee ranking minority member Matsui (D-Calif.). Among the witnesses testifying in support of the measure will be Genzyme VP-Government Relations Lisa Raines. Johnson is also holding a hearing on establishing a more general permanent R&D tax credit on May 10...